TrialAnnals of oncology : official journal of the European Society for Medical Oncology2013

N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial.

W W Tan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.